Just read the FDA approved Enherta with a 60% response rate. It is a drug to treat HER-2 positive breast cancer. Enherta has an incredibly long list of reported serious risks and side effects. If Leronlimab's early results treating cancer continue to be promising with no SAEs or significant SEs, than whatever upside we expect for CYDY is probably too modest. As a CYDY shareholder since 2015, I have witnessed the potential benefits of Leronlimab increase each year. I am optimistic that 2020 will see Leronlimab continue on the path to FDA approval and eventually become the SOC for many different serious and life threatening conditions.

Merry Christmas and a Happy New Year to all!